{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:58:17Z","timestamp":1770962297688,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1741,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:p>Pharmacotherapy for depression is often necessary during pregnancy. The information available about use of the newer antidepressants in pregnant women is limited by trial design and lack of long\u2010term follow\u2010up of exposed infants. Selective serotonin reuptake inhibitors (SSRIs) are not generally thought to be major teratogens. Some recent studies, however, have suggested that paroxetine may be associated with a small increase in risk of congenital abnormalities, particularly cardiac defects. Data on the effect of SSRIs on the incidence of preterm birth, spontaneous abortion, and fetal death are conflicting. Third\u2010trimester exposure to newer antidepressants, including SSRIs and serotonin\u2010norepinephrine reuptake inhibitors (e. g., venlafaxine), has been associated with a poor neonatal adaptation syndrome. In addition, SSRI use may be associated with an increased risk of persistent pulmonary hypertension of the newborn. Preliminary evidence suggests that SSRI exposure in utero does not have significant long\u2010term effects on cognition or behavior. Based on limited information, mirtazapine, bupropion, and venlafaxine do not appear to be major teratogens. Little or no information is available on duloxetine.<\/jats:p>","DOI":"10.1592\/phco.27.4.546","type":"journal-article","created":{"date-parts":[[2007,3,26]],"date-time":"2007-03-26T08:47:38Z","timestamp":1174898858000},"page":"546-552","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Safety of Newer Antidepressants in Pregnancy"],"prefix":"10.1002","volume":"27","author":[{"given":"Cynthia M.","family":"Way","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/10401230490453662"},{"key":"e_1_2_1_3_2","first-page":"1087","article-title":"Depression during pregnancy","volume":"51","author":"Ryan D","year":"2005","journal-title":"Can Fam Physician"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370404901103"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.5.499"},{"key":"e_1_2_1_6_2","first-page":"660","volume-title":"Drugs in pregnancy and lactation","author":"Briggs GG","year":"2005"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351402"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.8.609"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050664"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.12.2055"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.139"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.172"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.05.012"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000187302.61812.53"},{"key":"e_1_2_1_15_2","unstructured":"GlaxoSmithKline Inc.Epidemiology study: updated preliminary report on bupropion and other antidepressants including paroxetine in pregnancy and the occurrence of cardiovascular and major congenital malformation. Available fromhttp:ctr.gsk.co.ukSummaryparoxetinestudylist.asp. Accessed October 9 2006."},{"key":"e_1_2_1_16_2","unstructured":"GlaxoSmithKline Inc.New safety information regarding paroxetine. September 29 2005. Available fromhttp:www.hc\u2010sc.gc.cadhp\u2010mpsmedeffadvisories\u2010avisprofpaxil_3_hpc\u2010cps_e.html. Accessed December 5 2005."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2005.11.006"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-004-0057-5"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.158.4.312"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.02.019"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701233360404"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E547"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.19.2372"},{"key":"e_1_2_1_24_2","first-page":"1077","article-title":"Taking antidepressants during late pregnancy: how should we advise women?","volume":"51","author":"Kalra S","year":"2005","journal-title":"Can Fam Physician"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.160.2.173"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.066431"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052744"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.11.1889"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.10.1728"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2004.07.004"},{"key":"e_1_2_1_31_2","first-page":"1707","volume-title":"Drugs in pregnancy and lactation","author":"Briggs GG","year":"2005"},{"key":"e_1_2_1_32_2","volume-title":"Cymbalta (duloxetine) product monograph","author":"Eli Lilly and Company.","year":"2005"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0817"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103017001716"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-005-0007-0"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.09.027"},{"key":"e_1_2_1_37_2","article-title":"Bupropion in pregnancy and the prevalence of congenital malformations","author":"Cole JA","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/14622200410001669169"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.27.4.546","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.27.4.546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:47:43Z","timestamp":1761043663000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.27.4.546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1592\/phco.27.4.546"],"URL":"https:\/\/doi.org\/10.1592\/phco.27.4.546","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}